Key Takeaways & Executive Findings
- •• Structured diabetic foot care education reduced foot ulcer incidence by 47% over 12 months in patients with type 2 diabetes. • Patients receiving education showed significant improvements in foot self-care behaviors and knowledge scores. • The intervention improved quality of life, with no significant adverse effects. • Findings support routine integration of structured foot care education into diabetes management programs.
Abstract
Background: Diabetic foot complications are a major cause of morbidity and mortality in patients with type 2 diabetes. Patient education is a cornerstone of preventive care, but its efficacy in real-world settings remains debated. Methods: In a randomized controlled trial, 240 patients with type 2 diabetes were assigned to either a structured diabetic foot care education program (intervention group) or standard care (control group). The primary outcome was the incidence of foot ulcers over 12 months. Secondary outcomes included foot self-care behaviors, knowledge scores, and quality of life. Results: The intervention group showed a significantly lower incidence of foot ulcers (8.3% vs. 15.8%, p=0.03) and improved foot care knowledge and behaviors compared to controls. Quality of life scores were also higher in the intervention group. Conclusion: Structured diabetic foot care education significantly reduces foot ulcer risk and improves self-care behaviors in patients with type 2 diabetes, supporting its integration into routine diabetes management.
1. Introduction
Diabetic foot complications, including ulcers and infections, are a leading cause of hospitalization and amputation in patients with type 2 diabetes. Despite advances in glycemic control and vascular care, the incidence of diabetic foot ulcers remains high, with a lifetime risk of up to 25%. Patient education is widely recommended as a preventive strategy, yet its efficacy in real-world settings is often questioned due to variability in program content and delivery.
Previous studies have shown that educational interventions can improve foot care knowledge and self-reported behaviors, but evidence on clinical outcomes such as ulcer incidence is limited. Moreover, the optimal structure and intensity of education programs are not well defined. This randomized controlled trial aims to evaluate the efficacy of a structured diabetic foot care education program on ulcer incidence and self-care behaviors in patients with type 2 diabetes.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang (2026). Efficacy of Diabetic Foot Care Education in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study found that a structured diabetic foot care education program significantly reduced the incidence of foot ulcers by 47% over 12 months in patients with type 2 diabetes, compared to standard care.
How many patients were included in the trial?
A total of 240 patients with type 2 diabetes were enrolled and randomly assigned to either the intervention group (structured education) or the control group (standard care).
What were the secondary outcomes measured?
Secondary outcomes included foot self-care behaviors, knowledge scores, and quality of life, all of which improved significantly in the intervention group.
Are there any limitations to this study?
The study was conducted at a single center, which may limit generalizability. Additionally, the follow-up period was 12 months, so longer-term effects are not assessed.
What are the clinical implications of this research?
The findings support the integration of structured foot care education into routine diabetes management to reduce the risk of foot ulcers and improve patient outcomes.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.